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We present development and human application of a method for determining the regional cerebral density of the type 
2 vesicular monoamine transporter (VMAT2) using positron emission tomography (PET) and [ "C] dihydrotetrabenazine 
(DTBZ). Previous animal studies indicate striatal W T 2  density is linearly related to the integrity of substantia nigra 
dopamine neurons and is not subject to drug- or lesion-compensatory regulation. In the present studies, kinetic compart- 
mental modeling was employed to estimate blood-brain ["CIDTBZ transport (lir,) and Vh4AT2 binding site density 
(tissue-to-plasma DTBZ distribution volume, DV) from the cerebral and plasma DTBZ time courses h e r  intravenous 
tracer injection. In controls, we found reductions of putamen DTBZ DVwith advancing age, corresponding to losses 
of 0.77% per year in specific VMAT2 binding. Parkinson's disease (PD) patients had reduction in specific DTBZ DV 
in the putamen (-61%) and in the caudate nucleus (-43%). There was no overlap of lowest specific putamen DTBZ 
DVbetween individual elderly controls and PD patients. The present results indicate the suitability of ["CIDTBZ PET 
for objective quantification of nigrostriatal integrity, including evaluation of PD progression and its possible therapeutic 
modification. 
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Pathological losses of dopaminergic neurons in the ven- 
tral midbrain and their striatal terminals are well recog- 
nized in idiopathic Parkinson's disease (PD) [l,  21 and 
in other neurodegenerative extrapyramidal movement 
disorders such as multiple system atrophy [3] and pro- 
gressive supranuclear palsy [4]. Despite this knowledge, 
the pathophysiology of selective nigrostriatal injury, 
and thus therapies to slow or arrest the progression of 
PD, are unknown. Effects of environmental toxins [ 5 ,  
61, genetic predisposition [7], oxidative stress [S, 91, 
and even differing symptomatic therapies [lo,  111 on 
the development and progression of PD have been pro- 
posed. An objective, noninvasive marker of nigrostriatal 
pathology would be helpful to advance our current un- 
derstanding of PD and to permit direct testing of these 
hypotheses. 
Several radiotracers have been employed previously 
to image nigrostriatal terminals and the changes in PD 
in vivo, including ["F] AuoroDOPA (FDOPA) [12], 
["Clnomifensine [13], ["CJWIN 35,428 [14], and 
[I2'I] P-CIT [ 1 51. Unfortunately, the processes revealed 
by these ligands are subject to drug-induced and dis- 
ease-compensatory regulation, limiting their abilities to 
quantify accurately PD lesion severity [ 161. In the pres- 
ent studies, we introduce the novel ligand ["Cldihy- 
drotetrabenazine ([ "CIDTBZ) for in vivo binding esti- 
mates of the type 2 vesicular monoamine transporter 
(VMAT2) in the human brain. Prior studies of this 
presynaptic monoaminergic binding site in experimen- 
tal animals indicate that it is not regulated readily by 
conditions that alter the synthesis, turnover, or release 
of dopamine [17, 181. Further, its striatal concentra- 
tion is highly correlated with the number of intact ni- 
gral dopaminergic neurons following graded neuro- 
toxin lesions [ 191, suggesting that VMAT2 density may 
be an objective marker of nigrostriatal terminal integ- 
rity. The current studies extend our investigations of 
["CIDTBZ biodistribution to the human brain with 
positron emission tomography (PET), including devel- 
opment of a quantitative PET VMAT2 assay, examina- 
tion of VMAT2 binding in normal aging, and a com- 
parison with PD patients. In an accompanying report, 
["CIDTBZ binding to straital VMAT2 in patients 
with multiple system atrophy or sporadic olivoponto- 
cerebellar atrophy is examined [2O]. 
Subjects and Methods 
Metabolism and Chromatography o f  DTBZ 
Preclinical studies were conducted with [3H]DTBZ in the 
rat to detect the presence of radiolabeled metabolites of 
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["CIDTBZ in blood and tissues and to establish a rapid 
chromatographic method for assay of authentic DTBZ in 
plasma. (9-0-[ 'HJMethoxy)DTBZ (sp act, 82 Cilmmol) 
was custom synthesized from the desmethyl precursor and 
[ W]CH,I (Aniersham Corp, Arlington Heights, IL,). Ap- 
proximately 15 minutes after intravenous injection of 1 mCi 
[ "]DTBZ in a 225-grn male Sprague-Dawley rat, arterial 
blood was sampled and the rat was killed by intravenous 
injection of pentobarbital followed by saturated K(:l to pro- 
duce cardioplegia. Plasma aliquots were analyzed by liquid 
scintillation spectroscopy both directly and after depro- 
teination by the addition of 3 volumes of absolute ethanol 
and centrifugation at 10,000 x g for 10 min. Samples of 
brain and liver were homogenized in ethanol (3: 1 ,  volltissue 
weight), and aliquocs of the total homogenates and postcen- 
trifugation supernatants were assayed to assess recovery. Ad- 
ditional aliquots of the ethanolic cissue and plasma superna- 
tants were concentrated under vacu~tni and further analyzed 
by thin-layer chromatography (TLC) on silica gel plates (E. 
Merck no. 5721, Darmstadt, Germany) with a mobile phase 
of chloroformlmethanol 96 : 4. Chromatograins were autora- 
diographed by apposition to x-ray film (SB5. Eastman Ko- 
dak, Kochester, NY) at  -70°C for 3 days with the use of a 
fluorographic enhancer (En'hance, Arnershani Corp). Labeled 
species identified in the autoradiograms were scraped from the 
TLC plates and assayed by liquid scintillation spectroscopy. 
Samples of radiolabeled, polar ['HIDTBZ metabolites ob- 
tained from 1LC of liver were employed in conjunction with 
authentic [ 'HIDTBZ to develop a rapid liquid chroniato- 
graphic procedure for their separation. Samples of DTBZ or 
labeled metabolites were applied to Whatman Sep-I'ak C,, 
chromarography columns (Waters Division, Millipore Corp, 
Milford, MA) in 1 ml of phosphate-buffered saline (PBS; 
NaCl 124 mM, KCI 2.7 mM, Na,HPO, 7.7 mM. KH,PO, 
1.5 mM, pH 7.4) and eluted with 9 ml ethanollPBS mobile 
phases of varying proportion followed by 5 ml of absolute 
ethanol. Eluates were assayed in sequential 1-ml fractions by 
liquid scintillation spectroscopy to determine both elution 
profile and sample recovery. 
Su 6ject.s 
Six young (age, 26 2 4 years; range, 22-34 years; 2 females, 
4 males), 3 middle-aged (age, 47 t 4 years; 44-52 years; 3 
females), and 6 elderly (age, 64 -t 5 years; range 57-70 
years; 1 female, 5 males) normal subjects were studied in 
comparison with 7 PD patients (age, 67 -C 7 years; range, 
57-73 years; 2 females, 5 males). The PD patients each had 
the cardinal signs of resting tremor, bradykinesia, and rigidity 
with symptomatic and objectively documented respon- 
siveness to levodopa. The patients ranged in severity between 
stages I and 111 on the Hoehn and Yahr scale [21], with 
symptomatic durations of illness between 3 and 10 years. 
Normal subjects were receiving no centrally acting niedica- 
tions, whereas the PD patients were receiving levodopa/carbi- 
dopa, aniantadine, or deprenyl; antiparkinsonian medica- 
tions were not discontinued prior to ["CIDTBZ imaging. 
The experimental protocol was approved by The University 
of Michigan committees on the use of human subjects in 
research and on the human hie of radioisotopes, and written 
informed consent was obtained prior ro all procedures. 
["CJDTBZ Scrlns 
Carbon- 1 1 -labeled, racemic (?)-DTBZ was prepared by 
methylation of the desriiethyl precursor as described previ- 
ously [22, 231. 'The specific activity of ["CIDTBZ was de- 
termined by high-performance liquid Chromatography and 
ultraiolet absorption spectrometry in conjunction with ra- 
dioassay in an ionization chamber, and was routinely in the 
range of 500 to 1,000 Cilnimol at end-of-synthesis. 
Subjects were studied in a Siemens-CTI 921 Exact tonio- 
graph, which images a 15.8-cni axial field-of-view and per- 
mits reconstrucrion of 47 contiguous 3.375-mm-thick axial 
slices in the septa-in scanning configuration. All subjects were 
studied supine, with eyes and ears unoccluded. resting quietly 
in a dimly lit room. After the catheterization of a radial ar- 
tery and contralateral antecubital vein, four porous beads of 
approximately I-mm diameter were labeled with 1 pCi 
["CIDTBZ and affixed to widely separated locations on the 
scalp, within the scanned field-of-view. Scans were then initi- 
ated with the bolus intravenous injection of approximately 
18 mCi ["CIDTBZ containing less than 50 pg of mass. 
Dynamic PET imaging of the head was performed over 60 
minutes according to the following schedule: 4 X 30-second, 
3 x I-minute, 2 X 2.5-minute, 2 X 5-minute, and 4 X 
10-minute scan durations. Scans were reconstructed by filtered 
back projection employing a Hanning filter with cutoff fre- 
quency of 0.5 cycleslray and calculated attenuation correction. 
Dynamic sequences ofscans were next corrected for subject mo- 
tion during the session on the basis ofthe fiducial scalp markers. 
The locations of the beads were identified in a reference frame 
and all other frames in the time sequence were reoriented (6 
degrees of freedom, three translational and three rotational) to 
bring the fiducials to rhesamecoordinates throughout the entire 
sequence. Anatomically configured regions of interest corre- 
sponding to the midfrontal cortex, caudate nucleus, putamen, 
thalamus, and cerebellum were applied to the sequence of ini- 
ages in each subject's scan. Regional boundaries were defined 
on summed ["CIDTBZ activity maps from 0 to 7.5 minutes 
after injection, and were applied in parallel to the three contigu- 
oils axial slices that best represented the body of the thalamus 
(thalamus and frontal cortex), the striatuni (caudate and puta- 
men), and the midcerebellum. 
Heparinized arterial blood was collected at 10-second in- 
tervals for 2 minutes, followed by additional samples at 2.5, 
3, 4 ,  5 ,  7.5, 10, 15, 30, 45, and 60 minutes after injection 
of [ "C] DTRZ. After centrifLigation, total plasma activity was 
determined in aliquots with a sodium iodide well counter. 
Aliquots at I-minute, 2-minute, 3-minute, and later postin- 
jection times were processed in parallel for determination of 
radiolabeled metabolites. Plasma (0.5 ml) was added to I'BS 
(0.5 nil) containing approximately 0.05 pCi of authentic 
['HIDTBZ, and the sample was applied to a Sep-Pak C! ,  
chromatography column. The eluates (1) from initial loading 
combined with a subsequent wash with 9 ml of I'BSlethanol 
65:35;  and (2) from a subsequent wash with 5 nil of absolute 
ethanol were assayed for carbon-1 1 activity in the ~ e l l  
counter. After decay of the carbon-1 1, aliquots of the two 
eluates were assayed for tritium content by liquid scintillation 
spectrometry. The distributions of total carbon-1 1 and 
[ 'HIDTBZ were then employed to calculate the fractions of 
authentic [ "C]DTBZ and carbon-1 1 -labeled metabolites in 
plasma, as described previously [24] 
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Parametric Analyses of D TBZ Distribution 
Estimates of tracer delivery to brain were derived from the 
blood-brain barrier rate parameter (k;) and of VMAT2 
binding site density from tissue-to-blood tracer distribution 
volumes (DVs), each determined from cerebral and me- 
tabolite-corrected arterial plasma ["CIDTBZ time-activity 
curves (see Appendix). In prior studies with reversible bind- 
ing ligands, the total tissue DV has been investigated and 
established as an estimate of binding site density 125, 261. 
The total DVparameter has the advantage of favorable preci- 
sion and stability; however, it contains contributions of non- 
specific and free ligand in addition to that of specific bind- 
ing. We also estimated, as follows, the component of total 
DTBZ DV attributable to specific binding with the use of 
the frontal cortex as a reference region essentially devoid of 
VMAT2 binding sites relative to the normal striatum: 
Our assumption of minimal specific DTBZ binding in the 
frontal cortex relative to the striatum is supported by ( I )  in 
vitro VMAT2 binding results in rodent and human brain 
that indicate cortical binding levels between 5% and 8% of 
those in the caudate nucleus and putamen [19, 271; and 
(2) relative levels of monoamines in human brain indicating 
cortical values of less than 1% of the caudata nucleus 1281. 
Data Analysis and Statistics 
Parametric regional determinations of DTBZ rC; and total 
DVwere averaged from left and right hemispheres and as- 
sessed with one-way analysis of variance (ANOVA) (within 
brain region) across young, middle-aged, and elderly normal 
and PD patient groups. Data from regions demonstrating 
significant ANOVA were then examined with painvise Stu- 
dent's t tests for difference from the elderly controls. Addi- 
tional comparisons of K; patterns were performed after ex- 
pressing an individual's regional parameters relative to that 
of the frontal cortex and on the specific Or/: as defined 
above, with the use of the frontal cortex to estimate the 
nonsaturable total DV components. A significance threshold 
of p < 0.05 was employed throughout. 
The possibility of age-related changes in rC; or DVwas 
further examined by linear regression analyses of parametric 
and relative parameter values. To facilitate comparisons with 
prior striatal aging data, apparent effects were expressed in 
linear (zero order) rates of change relative to extrapolated 
parameter values at birth (age, 0 years). 
Results 
Metabolites and Chromatography of ( I 1  C/o TBZ 
After systemic injection in the rat, ['HIDTBZ and po- 
lar metabolites were identified in the liver and plasma, 
but only authentic DTBZ was recovered from the 
brain (Fig 1). In  plasma, two groups of polar metabo- 
lites migrated at or near the origin on  TLC. Liver chro- 
matograms revealed similar bands of activity and an- 
other minor band of lower polarity. After isolation of 
the two predominant metabolite groups from liver, 
preliminary liquid chromatography studies revealed 
Fig 1. Autoradiopaphic visualization of ('H]dihydrotetra- 
benazine (['HIDTBZ) and labeled metabolites fiom rat tis- 
sues. Samples o f  stock rH]DTBZ (STD) and activities 
recovered from brain, plasma, and liver 15 minutes ajier 
injection were separated by thin-layer chromatography (TLC) 
and visualized by autoradiography. Subsequent Liquid scintilla- 
tion spectroscopy revealed more than 97% and 99% of  total 
activity in the DTBZ standard and brain samples correspond 
to authentic D TBZ, respectively. Polar metabolites account for  
14% and 7% of recovered activity from plasma and liver. 
0 = chromatographic origin; SF = solventfiont afier TLC 
deuelopment; * = DTBZ. 
that they could be quantitatively removed from Sep- 
P a k  CIS columns by elution with PBS/ethanol 65:35. 
This resulted in retention of more than 70% of authen- 
tic DTBZ on the column, which was subsequently re- 
coverable in absolute ethanol. These chromatographic 
conditions were applied routinely in subsequent analy- 
ses of human plasma samples. 
Human Phsma Activity uJter DTBZ Injection 
After intravenous bolus injection of ["CIDTBZ in hu- 
man subjects, total plasma activity peaked rapidly and 
then declined by 20- to 50-fold within 5 minutes after 
injection (Fig 2A). Chromatography routinely revealed 
polar, labeled DTBZ metabolites after 5 minutes after 
injection that accounted for more than 50% of total 
plasma activity at the end of the 60-minute imaging 
period. 
Normal Human Cerebral Distribution of DTBZ 
Initial uptake of ["CIDTBZ was relatively homoge- 
neous and higher across gray matter than in white mat- 
ter structures, consistent with the known pattern of 
cerebral blood flow. Within 3 to 5 minutes after injec- 
tion, however, higher retention in the striatum was eas- 
ily distinguished from other gray matter regions (Fig 
2B). Between 5 and 7 minutes after injection, activity 
began to decline throughout the brain with slowest 
clearance from the caudate and putamen. 
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between ages 20 and 70 years. Similar but statistically 
insignificant declining trends were found in the thala- 
____ 
%-- 
mus and cerebellum (reductions of 0.47% and 0.36% 
per year, respectively). 
Binding of [“CIDTBZ as reflected by the total tis- 
sue-to-plasma DV was regionally heterogeneous, dis- 
playing a 2.2-fold difference between putamen and cer- 
ebellum in young normal subjects (Table 2, see Fig 3).  
Total DV estimates were not significantly affected by 
age; however, there was a trend toward decline in stria- 
tal regions in the elderly controls. When specific DV 
was examined, a significant decline of 0.77% per year 
6o was revealed in the putamen (see Table 2; Fig 4) .  
Parkinson ? Disease 
Significant reductions in specific DTBZ DV were ob- 
served in the bilaterally averaged whole putaminal 
(-61%) and caudate nucleus (-43%) regions in PD 
compared with elderly controls (see Table 2). In con- 
trast to DTBZ Or/: k; values in the PD group tended 
to be higher than the elderly controls, achieving statis- 
tical significance in the cerebellum (see Table 1). When 
expressed relative to frontal cortex, the K pattern in 
PD was virtually identical to that of the elderly controls 
45 60 and demonstrated no trend toward reduction in the :....-: 0 15 30 
striatal regions. Time Post-Injection, min 
0 15 30 45 
09 
Fig 2. Time-activi9 curves afier [I’ CJdihydrotetra benazine 
((“C]D TBZ) in a young normal subject. (A) Decay-corrected 
activities corresponding to total (open circles, dashed line) 
and authentic DTBZ (filled circles, solid line) after rapid 
column chromatography are depicted. Note evidence f o r  
labeled metabolites ajer 5 minutes, accounting for  more than 
50% of  total activity at 60 minutes. (B) Decay-corrected 
activities corresponding to regions-of- intcrest placed over the 
putamen (circles), thalamus (squares), and fiontal cortex (tri- 
angles) are depicted together with the curves predicted by the 
model pavumeters determined in nonlinear least-squares analy- 
sis employing a three-compartment kinetic model (see Appen- 
dix). Note clear distinctton o f  the putumen from other regions 
within 5 to 7.5 minutes aft.. injection. 
Efect  of Age on DTBZ Tmnsport and Binding 
Blood-to-brain transport of [”C]DTBZ revealed simi- 
lar values across the gray matter regions studied (Table 
1, Fig 3), with average K values between 0.29 and 
0.34 ml of plasma/ml of brainlmin in young normal 
subjects. The elderly controls demonstrated diminished 
in most of the regions studied. There were no group 
differences in the pattern of k; after expression relative 
to the frontal cortex, suggesting that the dominant 
aging effect on transport is a global reduction. Linear 
regression analyses revealed statistically significant de- 
clines in the striatal and cerebral cortical regions be- 
tween 0.68% and 0.75% of extrapolated 4 at birth 
per year, corresponding to approximately 35% declines 
Regional analyses of individual PD patients’ scans 
revealed reductions in whole-putaminal specific D x  
DVwas reduced below 2 SD of elderly control mean 
on at least one side in 5 of the 7 PD patients (Table 
3). Considering the lowest specific putaminal DV in 
each elderly control and PD subject, there was no over- 
lap between the two groups (elderly normal range, 
0.41-0.95; PD range, 0.08-0.40). Inspection of pixel- 
by-pixel DV maps revealed clear reductions in putanii- 
nal D V i n  each PD subject, with the most severe loss 
in the posterior putamen (Fig 5 ) .  In each patient, the 
DTBZ DV was reduced to cerebral cortical levels in 
the posterior putamen on at least one side. In contrast, 
the entire putamen was well distinguished from adja- 
cent cerebral cortex bilaterally in each elderly control. 
When reductions in PD patients’ putamen DVmea- 
sures were asymmetric, the most affected putamen was 
that contralateral to the most affected limbs. 
Discussion 
Measurement of VMA T2 with [I’ CJD TBZ 
The present work describes development and initial 
clinical research application of [ ”ClDTBZ for nigro- 
striatal nerve terminal integrity measurement. The 
VMAT2 marker, targeted by DTBZ, has been shown 
previously to possess important characteristics related 
to its potential utility in neurodegenerative diseases. In 
the central nervous system, VMAT2 is expressed exclu- 
sively by monoaminergic neurons, including those uti- 
lizing dopamine, serotonin, norepinephrine, or hista- 
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Table 1. Plasma-to-Brain [“C]DTBZ Transport,‘ 
Frontal Cortex Caudate Putamen Thalamus Cerebellum 
~~~~ ~ 
Parametric K, 
Young normal 0.31 L 0.07’ 0.31 t 0.09” 0.34 -+ 0.10‘ 0.34 +- 0.06 0.29 i 0.05 
Middle-aged normal 0.34 -+ 0.06” 0.35 2 0.06” 0.38 C 0.07‘ 0.42 i 0.11‘ 0.35 2 O.OGh 
Elderly normal 0.21 -+ 0.07 0.20 i 0.07 0.22 C 0.08 0.26 2 0.09 0.20 t 0.07 
Parkinson’s disease 0.27 -+ 0.04 0.27 i 0.06 0.30 i 0.06 0.34 2 0.06 0.29 2 0.05‘ 
K; relative to frontal cortex 
Young normal - 1.00 t 0.17 1.09 -+ 0.16 1.11 i 0.14 0.93 2 0.08 
Elderly normal - 0.99 F 0.15 1.07 -+ 0.16 1.26 2 0.04 0.99 i 0.16 
Middle-aged normal - 1.03 2 0.04 1.11 -+ 0.02 1.23 2 0.12 1.03 2 0.04 
Parkinson’s disease - 1.00 i 0.10 1.08 t 0.11 1.23 2 0.10 1.07 2 0.12 
Values represent the mean t SD of parametric K; estimates (ml of plasma/ml of brainimin) from three-compartment regional analyses, or 
1(1 expressed relative to that of frontal cortex, from 6 young, 3 middle-aged, and 6 elderly normal controls and 7 Parkinson’s disease patients. 
”Significant difference from elderly normal after one-way (within-region) analysis of variance at the p < 0.05 level by Student’s t test. 
DTBZ = dihydrotetrabenazine. 
Fig 3. Parametric images of dibydrotetrabenazine (D TBZ) transport (K,) and total distribution volume (DV) from a representa- 
tive young normal subject. DTBZ K, (top row) and totul DV (bottom row) fiom a two-compartment, pixel-by-pixel estimation 
(see Appendix) are shown in five transaxial slices fiom supraventricular (lefi column) to the posterior fissa (right column) levels. 
The bright spots on the scalp at the top o f  images in columns 1 and 3 are due to the Iabeledjducial markers usedfor dynamic 
image realignment. 
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Table 2. [‘I C]D TBZ Distribution Volume 
Frontal Cortex Caudate Putamen Thalamus Cerebellum 









Specific D V  
3.7 t 0.6 
4.3 i 0.5 
4.0 t 0.8 





7.4 t 2.5 8.2 t 2.8 
7.9 ? 1.0 8.3 t 1.2 
7.0 t 1.5 6.8 i 1.4 
5.6 I 1.3 5.1 _f 1.2h 
0.97 t 0.38 
0.84 i 0.12 
0.76 t 0.18 
0.43 f: 0.26h 
1.18 t 0.45” 
0.95 2 0.18 
0.70 i 0.19 
0.27 t 0.11‘ 
3.9 t 0.6 3.7 ? 0.8 
4.6 t 0.5 4.3 t 0.8 
4.3 I: 1.0 3.7 -C 0.8 
3.9 _f 0.9 4.1 i 1.0 
0.05 i 0.04 -0.02 t 0.07 
0.07 t 0.02 0.00 2 0.12 
0.06 i 0.06 -0.06 t 0.13 
-0.02 t 0.04 0.01 i 0.07 
‘Values represent the mean -t SD of parametric total D V  estimates (ml of plasma/ml of brain) from three-compartment regional anaiyses, 
or specific DVwith the use of frontal cortex to estimate the nonsaturable DVcomponent. 
bSignificant difference from elderly normal after one-way (within-region) analysis of variance at the p < 0.05 level hy Student’s t test. 
‘Significant difference from elderly normal at the p < 0.001 level by Student’s t test. 
DTBZ = dihydrotetrabenazine; DV = distribution volume. 
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Age, y e a r s  
Fig 4. Effect of  normal aging on dihydrotetrabenazine 
(DTBZ) total distribution volume (DV). (A) Total tissue 
DV (ml o f  plasmalml of tissue) determined regionally with a 
three-compartment kinetic model (see Appendix) is depicted in 
the putamen (filled squares, DV = 9.204 - 0.034 [Age]: 
r = 0.303, p = 0.272) and in the frontal cortex (filled 
circles, DV = 3.658 + 0.006 [Age]; r = 0.169, p = 
0.547). (B) Spec@ DTBZ DV in the putamen. A sign$- 
cant decline witb aging is identijied: DV = 1.432 - 0.011 
[Age]; r = 0.531, p = 0.042. 
mine [27, 291. In both the rat [19] and human [30] 
striatum, however, the relative abundance of dopamine 
terminals of the nigrostriatal system renders more than 
95% of the VMAT2 signal specific to this projection. 
Lesion studies in experimental animals verify that there 
is a linear correlation between substantia nigra pars 
compacta neuron integrity and ipsilateral striatal 
VMAT2 binding density [ 191, although residual bind- 
ing to nondopaminergic VMAT2 sites may dominate 
after profound nigrostriatal reductions. Furthermore, 
there is evidence that VMAT2 does not undergo com- 
pensatory up- or down-regulation under conditions 
that alter the synthesis or release of dopamine or that 
alter the occupancy of dopamine receptors in experi- 
mental animals [17]. Thus, striatal DTBZ binding is 
a sensitive and specific marker of nigrostriatal dopa- 
minergic innervation. A practical advantage of in vivo 
VMAT2 assys is that measures can be performed with- 
out discontinuation of symptomatic DOPA-mimetic 
therapy, as indicated by recent studies in experimental 
animals [31]. A relative disadvantage of VMAT2 as an 
imaging target may be its wide expression in the brain, 
precluding the use of a reference region entirely devoid 
of specific binding. As indicated in the present studies, 
however, this may not limit use of reference regions 
such as the cerebral cortex or cerebellum for estimation 
of specific striatal binding, since the latter regions have 
very high relative VMAT2 levels. Nevertheless, experi- 
mental designs must guard against changes in the cho- 
sen reference region, as may be assessed by the para- 
metric (relative to blood) total DTBZ DV. 
In contrast to the relationship between nigrostriatal 
terminal numbers and VMAT2 sites, other presynaptic 
dopaminergic imaging markers identify aspects that are 
now appreciated to undergo compensatory regulation. 
Uptake of the earliest in vivo imaging marker of striatal 
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Table 3. Specz$c Putamen [" C]D TBZ Distribution Volumes in Individual Parkinson j. Disease Patients 
Age (yd/ Duration (yr)/ 
Patient No. Sex Staged Medicationsb 
Putamen / Cortex 
["CIDTBZ D V  
Left Right 








Levodopa, 300 mg 0.37 0.38 
Levodopa, 480 mg 0.15 0.50 
Amantadine, 300 mg 
Levodopa, 750 mg 0.26 0.31 
Levodopa, 300 mg 0.40 0.43 
Deprenyl, 10 mg 
Levodopa, 840 mg 0.08 0.17 
Deprenyl, 5 mg 
Levodopa, 680 mg 0.24 0.16 
Deprenyl, 10 mg 
Levodopa, 740 mg 0.15 0.15 
Deprenyl, 5 mg 
'Duration of PD symptoms and disease severity as assessed on the scale of Hoehn and Yahr [21] at the time of PET scanning. 
bTotal daily doses of medications at the time of PET scanning. Continuous release levodopa (Sinemet CR) doses were scaled by 0.80 to 
reflect incomplete bioavailability of chis preparation. 
'Individual, whole putamen, specific DTBZ DK Values for elderly normal subjects average 0.70 f_ 0.19 (range, 0.41-0.98). Patient values 
less than 0.32 are 2 SD below normal and are considered significantly reduced. 
DTBZ = dihydrotetrabenazine; DV = distribution volume; P D  = Parkinson's disease; PET = positron emission tomography 
dopamine terminals [I8F]FDOPA, is predominantly re- 
lated to the activity of DOPA decarboxylase (DDC) 
[32]. Although regulation of the rate-limiting dopa- 
mine synthetic enzyme tyrosine hydroxylase is well 
known, only recently has evidence for regulation of 
subsequent DOPA decarboxylation been sought. The 
decarboxylation rate has now been shown to be regu- 
lated by negative feedback from presynaptic dopa- 
mine D2 autoreceptors [33-361. Thus, diseases or 
treatments that reduce synaptic dopamine levels will 
maximally activate DDC, resulting in compensatory 
increase in ['*F]FDOPA accrual within surviving ter- 
minals. 
Several cocaine-analogue ligands have been intro- 
duced recently as markers of dopamine nerve terminals 
by virtue of their binding to the presynaptic, plasma 
membrane dopamine reuptake site (the dopamine 
transporter; DAT) . Radioligands including the posi- 
tron-emitting ["CIWIN 35,428 [14] and the single 
photon-emitting [Iz3I] j3-CIT [ 151 have successfully 
imaged striatal dopamine terminals in human brain. 
However, as in the instance of DDC, the DAT binding 
site density is subject to regulation by some drug treat- 
ments that alter synaptic dopamine levels and turnover, 
including classes of agents used in the symptomatic 
treatment of PD [17, 37-40]. 
Because of the merits of VMAT2 as a nigrostriatal 
marker, we have pursued several candidate radioligands 
for its determination in vivo with PET. Our initial 
selection, ["Cltetrabenazine (["CITBZ), permitted vi- 
sualization of the human striatum; however, quantifi- 
cation of the signal could not be achieved due to the 
presence and abundance of pharmacologically active, 
labeled metabolites, including ["CIDTBZ [41]. We 
next studied the metabolically directed TBZ analogue 
2- 0-methyldihydrotetrabenazine (methoxytetrabena- 
zine; MTBZ), radiolabeled in a position chosen to slow 
its rate of metabolism and to yield unlabeled metabo- 
lites after Odemethylation. We achieved successful 
quantification of human VMAT2 with ["CIMTBZ 
but discovered the presence of a minor labeled metabo- 
lite in rodent brain [16]. Our present studies with the 
TBZ metabolite DTBZ are even more encouraging. 
We find no evidence for labeled metabolites of DTBZ 
in brain and detect only polar metabolites in blood. In 
addition, the synthesis of ["C] DTBZ is accomplished 
with higher yield and reliability than those of 
[ "CIMTBZ. Finally, we have recently demonstrated 
both in vitro [23] and in vivo [42] that the isomers 
of the racemic DTBZ employed here display marked 
differences in VMAT2 binding affinity. After chiral 
chromatographic resolution of the desmethyl precursor, 
the active isomer (+)-["CIDTBZ has now' been pre- 
pared and demonstrates almost twofold higher relative 
human striatal accumulation than in the present studies 
[42]. Thus, future studies employing (+)-DTBZ 
should be even more sensitive to changes in VMAT2 
expression. 
The Nigrostriatal System i n  Aging 
The present results in normal subjects indicate a sig- 
nificant age-associated decline in VMAT2 in the puta- 
men. Regression analysis suggests loss of 0.77% per 
year of extrapolated specific DTBZ DV at birth. This 
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Fig 5. Parametric [ ' I  Cjdihydrotetrabenazine [" C]D TBZ) images in Parkinson 2 disease (PO). Pixel-bypixel maps of D TBZ trans- 
port and distribution volume (DV), estimated Jiom a simplzfed two-compartment model (see Appendix), are depicted in columns 
at a rnidstriatal level Jiom representative control and PD subjects. ["CJDTBZ transport (top row), total DV (middle row), and 
spec@ DV (bottom row) arts displayed for  each subject. Note substantial DV reductions in the posterior striata of all PD patients 
and virtual absence of -Ipec$c DV in the most affected patient (right column). EN = elderly normal; PD I1 = Hoehn and Yahr 
[Zl] stage II PD; PD III = Hoehn and Yahr stage III PD. 
estimate is in good agreement with human postmorten 
studies on the loss of dopaminergic neurons from the 
substantia nigra pars compacta, suggesting 0.5 to 0.7% 
per year reduction [43, 441. Postmortem assay of hu- 
man striatal VMAT2 binding indicates a comparable 
age-associated loss of 0.74% per year [45]. Other labo- 
ratories have reported age-associated reductions in stri- 
atal DAT binding, both in vitro [46, 471 and in vivo, 
the latter assessed by PET with the use of ["Clcocaine 
[48] or by single-photon emission computed tomogra- 
phy with the use of ['''IlP-CIT [ 151. Estimated DAT 
changes are comparable with those indicated on our 
PET VMATZ data, and range from 0.3 to 0.950/0 per 
year reductions. 
In contrast to observed reductions in nigral neurons, 
VMAT2, and DAT, PET estimates of nigrostriatal in- 
nervation on the basis of [I8F]FDOPA uptake have re- 
vealed equivocal, conflicting evidence for change with 
advancing age. Two studies report age-associated de- 
clines of striatal FDOPA uptake between 0.3% and 
0.7% per year [49, 501. However, two additional re- 
ports from other laboratories fail to confirm these de- 
creases, indicating unchanged [5 I ]  or slightly increased 
[52] striatal FDOPA uptake between 27 and 77 years 
of age. In agreement with these latter negative findings, 
Kish and co-workers [53] have recently examined 
D D C  protein concentration in vitro. They report mild 
reduction in the caudate nucleus and no significant de- 
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cline in the putamen between ages 17 and 103 years, 
suggesting relatively increased expression of DDC per 
nerve terminal in aging. 
Parkinson ? Discizse 
Results of the present studies are encouraging regarding 
the use of [ . C ] D T B Z  to map and quantify the nigro- 
striatal terminal changes in PD. In agrecment with 
postmortem VMAT2 binding assays [45, 541, we iden- 
tified near-complete loss of specific DTBZ binding in 
the posterior putamen of each PD patient. We found 
no overlap of whole putamen-averaged DTBZ DV 
versus elderly controls, with significant individual pu- 
taminal reductions observed in 5 of 7 patients. Reduc- 
tions of whole putamen, specific, DTBZ D V o n  the 
most severely affected sides of our P D  patients averaged 
68% (range, 43-89%). These changes are in good 
agreement with postmortem observations, suggesting 
70-80% losses of striatal dopamine [2, 551 or of nigral 
neurons [44] are present when symptoms of PD are 
initially expressed. 
In addition to other neurochemical markers of ni- 
grostriatal injury, DAT binding is reduced by 90 to 
95% in postmortem P D  putamen [56-581. In vivo 
DAT imaging studies have clearly demonstrated these 
reductions in PD [13, 14, 591. DAT losses are corre- 
men. Combined with basic neurobiological evidence 
that VMAT2 binding site density is not subject to 
medication-induced or lesion-compensatory regulation, 
[”CIDTBZ is well suited to future studies of P D  pro- 
gression and to the investigation of possible disease- 
modifying aspects of its treatment. 
These studies were supported by grants to the investigators from 
the US Department of Energy and from chr Narional Institutes 
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respectively. R.L.A. was supported by the GRECC ‘it che Ann Arbor 
Veteran’s Administration Medical Center. 
Appendix 
Modeling of’ D TBZ Distribution 
A compartmental model incorporating intravascular 
tracer and free, nonspecifically bound and specifically 
bound tissue tracer pools (Fig 6) was employed for 
DTBZ DV estimation in the present studies. The 
model was simplified initially by combination of the 
nonspecific binding and free ligand pools, resulting in 
five parameters (blood volume and four intercompart- 
mental exchange rates) to be estimated. The D V  de- 
fined from the three-compartment, four-rate parameter 
model is as follows: 
D V =  rC, (1 + k3’/k+)/k2’ lated with the stage and severity of PD [53] ;  however, use of DAT binding to investigate possible disease- - .  
modifying aspects oftherapy may not be possible due 
to its regulation as discussed previously. 
Estimates of DDC with [‘*F]FDOPA suggest more 
modesr nigrostriatal losses than do our VMAT2 results. 
FDOPA K, values often exceed 50% of control putam- 
inal values in mild PD, and separation of P D  from 
normal without overlap requires contrast between max- 
imal caudate nucleus and minimal putamen K ,  [60] .  
I t  may be speculated that the relative preservation of 
FDOPA k; in PD striatum may result from up-regula- 
tion of DDC. This may arise chronically in association 
with accelerated dopamine turnover after partial de- 
struction of the nigrostriatal pathway [61, 621 and also 
acutely during the obligatory discontinuation of levo- 
dopa therapy for FDOPA scanning [63] .  In these in- 
stances, diminished synaptic dopamine levels may re- 
sult in reduced occupancy of yresynaptic D2 dopamine 
autoreceptors, leading to increased catalytic activity of 
DDC. 
Summary 
The present studies indicate the feasibility of imaging 
and quantification of VMAT2 sites in the human stria- 
turn with [”CIDTBZ and PET. Lesions of the nigro- 
striatal pathway in PD and normal ase-associated 
changes are demonstrated readily, without overlap of 
elderly normal and PD binding indices in the puta- 
where k; is the blood-to-brain transport rate, k?’ repre- 
sents brain-to-blood ligand transport, and k3’ represents 
binding to and k4 represents dissociation from specific 
VMAT2 tissue sites. The  ’ designations in the nota- 
tions k2’ and k,’ denote that they are apparent rates 
arising from combination of the tissue pools describing 
free and nonspecifically bound tracer. Kinetic regional 
estimates of DVwere made by nonlinear, least-squares 
analyses [64] of tissue and arterial blood time-activity 
curves, as follows: 
PET(t) = C l ( t ) ( l  - BV) + C,j(t)BV [21 
PET (t)  is the PET-determined tracer activity at time 
t, C, and C, are tracer concentrations in tissue and 
arterial blood, BVis the fractional tissue blood volume, 
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A 
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Fig 6 Physiologic compartmental model describing the distri- 
bution of dihydrotetrabenazine (D TBZ) in brain. (A) The 
most comprehensive model configuration includes ar te~al  
plasma tracer (C,) as well as individual representatioris of 
fiee tracer (Cp), nonspec$c binding (&), and speciJic bind- 
ing (CJ in tissue. Movement of tracer between compartments 
is governed by exchange rate constants designated K, and k2 
through k,. The forward ligand-receptor binding rate constant 
in the model, k,, is equivalent to  the product k,,z R, and the 
dissociation rate k4 denotes kofi where the available receptor 
concentration is denoted by R and the equilibrium binding 
afinity constant Kd = k,,/kdp (B) Two model simpliJcations 
employed in the present analyses are depicted The three-com- 
partment configuration (inner boxes, thin arrows) assumes 
rapid equilibration of f iee and nonspeciJically bound tracer in 
tissue, resulting in a new combined tissue pool (CF+NS)  and 
modijied rate parameters k,’ and k2‘, leading fiom it to the 
specifically bound and plasma tracer compartments, respec- 
tively. The modified rate parameters reflect underestimation o f  
the actual binding and tissue-to-blood clearance rates due to 
the lack of correction f o r  nonspecific binding in this configu- 
ratiorz. The two-compartment model configuration (outer 
boxes, thick arrows) was employed f i r  pixel-by-pixel estima- 
tion of DTBZ binding. In this instance, all tissue tracer is 
assumed within a single kinetic compartmmt, resulting in 
redaction to two-rate parameters K, and k:. The tissue-to- 
blood distribution volume (DV) is given by K,lk,”. 
and * represents the operation of convolution. In the 
fitting procedure, all parameters were constrained to 
positive values, and the value of k4 was constrained to 
be greater than 0.02/min, since the 60-minute period 
of PET observation does not permit accurate determi- 
nation of slower dissociation rates. 
A further simplified two-compartment model, com- 
bining all tissue tracer activities into a single kinetic 
compartment (see Fig 6), was also used for calculation 
of pixel-by-pixel estimates of and DV by a rapid, 
weighted integral, lookup table approach [65] where 
and 
The ” in the designation of apparent rate constant kc 
reflects its derivation from combining all three tissue 
compartments. 
Our initial kinetic compartmental analyses of race- 
mic [“CIDTBZ in normal subjects indicate that the 
specific binding to and dissociation from VMAT2 sites 
in the striatum are sufficiently rapid that the binding 
parameters k,’ and k4 cannot be precisely determined 
in isolation, as reported also for the resolved (+)- 
DTBZ isomer [66]. The total tissue Or/; estimated ei- 
ther from the three-compartment or the two-compart- 
ment models, reveals excellent correlation with the 
known distribution of VMAT2 sites. The two models 
lead to DV estimates that are linearly correlated with 
one another; however, the three-compartment config- 
uration leads to a broader dynamic range of DVvalues 
and better distinguishes regions of high and low 
VMAT2 site density. Thus, in the present studies, 
group differences in DV are assessed with the three- 
compartment model, while the detailed distribution of 
DV in individual subjects is depicted on a pixel-by- 
pixel basis with the two-compartment simplification. 
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